Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
Department of Orthopaedic Surgery, Kenshinkai Kobe Hokuto Hospital, 37-3 Yamada-cho Shimotanigami Aza Umekidani, Kita-ku, Kobe 651-1243, Japan.
Osteoarthritis Cartilage. 2019 Jun;27(6):965-976. doi: 10.1016/j.joca.2019.01.009. Epub 2019 Feb 1.
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates nutrients to execute cell growth. We hypothesized that mTOR is influential in the intervertebral disc-largest avascular, low-nutrient organ. Our objective was to identify the optimal mTOR inhibitor for treating human degenerative disc disease.
mTOR complex 1 (mTORC1) regulates p70/ribosomal S6 kinase (p70/S6K), negatively regulates autophagy, and is controlled by Akt. Akt is controlled by phosphatidylinositol 3-kinase (PI3K) and mTOR complex 2 (mTORC2). mTORC1 inhibitors-rapamycin, temsirolimus, everolimus, and curcumin, mTORC1&mTORC2 inhibitor-INK-128, PI3K&mTOR inhibitor-NVP-BEZ235, and Akt inhibitor-MK-2206-were applied to human disc nucleus pulposus (NP) cells. mTOR signaling, autophagy, apoptosis, senescence, and matrix metabolism were evaluated.
mTORC1 inhibitors decreased p70/S6K but increased Akt phosphorylation, promoted autophagy with light chain 3 (LC3)-II increases and p62/sequestosome 1 (p62/SQSTM1) decreases, and suppressed pro-inflammatory interleukin-1 beta (IL-1β)-induced apoptotic terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positivity (versus rapamycin, 95% confidence interval (CI) -0.431 to -0.194; temsirolimus, 95% CI -0.529 to -0.292; everolimus, 95% CI -0.477 to -0.241; curcumin, 95% CI -0.248 to -0.011) and poly (ADP-ribose) polymerase (PARP) and caspase-9 cleavage, senescent senescence-associated beta-galactosidase (SA-β-gal) positivity (versus rapamycin, 95% CI -0.437 to -0.230; temsirolimus, 95% CI -0.534 to -0.327; everolimus, 95% CI -0.485 to -0.278; curcumin, 95% CI -0.210 to -0.003) and p16/INK4A expression, and catabolic matrix metalloproteinase (MMP) release and activation. Meanwhile, dual mTOR inhibitors decreased p70/S6K and Akt phosphorylation without enhanced autophagy and suppressed apoptosis, senescence, and matrix catabolism. MK-2206 counteracted protective effects of temsirolimus. Additional disc-tissue analysis found relevance of mTOR signaling to degeneration grades.
mTORC1 inhibitors-notably temsirolimus with an improved water solubility-but not dual mTOR inhibitors protect against inflammation-induced apoptosis, senescence, and matrix catabolism in human disc cells, which depends on Akt and autophagy induction.
哺乳动物雷帕霉素靶蛋白(mTOR)是一种丝氨酸/苏氨酸激酶,可整合营养物质以执行细胞生长。我们假设 mTOR 对椎间盘(最大的无血管、低营养器官)有影响。我们的目的是确定治疗人类退行性椎间盘疾病的最佳 mTOR 抑制剂。
mTOR 复合物 1(mTORC1)调节 p70/核糖体 S6 激酶(p70/S6K),负调控自噬,并受 Akt 调控。Akt 受磷脂酰肌醇 3-激酶(PI3K)和 mTOR 复合物 2(mTORC2)调控。mTORC1 抑制剂雷帕霉素、替西罗莫司、依维莫司和姜黄素、mTORC1&mTORC2 抑制剂 INK-128、PI3K&mTOR 抑制剂 NVP-BEZ235 和 Akt 抑制剂 MK-2206 应用于人椎间盘核细胞。评估 mTOR 信号、自噬、凋亡、衰老和基质代谢。
mTORC1 抑制剂降低了 p70/S6K,但增加了 Akt 磷酸化,促进了自噬,增加了 LC3-II,减少了 p62/自噬相关蛋白 1(p62/SQSTM1),并抑制了促炎白细胞介素-1β(IL-1β)诱导的凋亡末端脱氧核苷酸转移酶 dUTP 缺口末端标记(TUNEL)阳性(与雷帕霉素相比,95%置信区间(CI)-0.431 至-0.194;替西罗莫司,95%CI-0.529 至-0.292;依维莫司,95%CI-0.477 至-0.241;姜黄素,95%CI-0.248 至-0.011)和多聚(ADP-核糖)聚合酶(PARP)和半胱天冬酶-9 切割,衰老相关的β-半乳糖苷酶(SA-β-gal)阳性(与雷帕霉素相比,95%CI-0.437 至-0.230;替西罗莫司,95%CI-0.534 至-0.327;依维莫司,95%CI-0.485 至-0.278;姜黄素,95%CI-0.210 至-0.003)和 p16/INK4A 表达,并释放和激活分解代谢基质金属蛋白酶(MMP)。同时,双重 mTOR 抑制剂降低了 p70/S6K 和 Akt 磷酸化,但没有增强自噬,并抑制了凋亡、衰老和基质代谢。MK-2206 拮抗了替西罗莫司的保护作用。额外的椎间盘组织分析发现 mTOR 信号与退行性变等级有关。
mTORC1 抑制剂,特别是水溶性更好的替西罗莫司,但不是双重 mTOR 抑制剂,可以防止人椎间盘细胞中炎症诱导的细胞凋亡、衰老和基质代谢,这取决于 Akt 和自噬的诱导。